RecruitingPhase 4NCT03102125
Allograft Dysfunction in Heart Transplant
Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients
Sponsor
Paul Kim
Enrollment
376 participants
Start Date
Oct 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Age greater than or equal to 18 years old.
- At least three months status post heart transplantation.
Exclusion Criteria12
- Biopsy proven acute rejection episode in the past 3 months.
- Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
- Uncontrolled obstructive ventilatory disease including asthma and COPD.
- History of generalized tonic-clonic seizures.
- Second or third degree AV nodal block.
- Sinus node dysfunction.
- Contraindications to MRI including cardiovascular implantable electronic devices.
- Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.
- Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.
- Systolic blood pressure greater than 180 or less than 85 mmHg.
- Diastolic blood pressure greater than 120 or less than 40 mmHg.
- Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.
Interventions
DRUGRegadenoson
For use in stress myocardial perfusion imaging.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03102125